Quarterly report pursuant to Section 13 or 15(d)

Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details)

v3.20.2
Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Revenues, net $ 204,199 $ 183,243
Operating income 49,092 33,327
Amortization of acquisition related intangible assets (15,501) (14,901)
Stock-based compensation, inclusive of employer taxes (13,333) (8,800)
Corporate general, selling, and administrative expenses (72,598) (69,010)
Operating Segments [Member]    
Operating income 79,026 60,438
Acquisition related expenses (136) (1,310)
Operating Segments [Member] | Protein Sciences [Member]    
Revenues, net 154,446 140,995
Operating income 70,352 59,538
Operating Segments [Member] | Diagnostics and Genomics [Member]    
Revenues, net 50,125 42,552
Operating income 8,674 900
Intersegment Eliminations [Member]    
Revenues, net (372) (304)
Corporate, Non-Segment [Member]    
Corporate general, selling, and administrative expenses $ (964) $ (2,100)